Drug Overview: DCVAC/PCa

  • ID: 4462229
  • Drug Pipelines
  • 16 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells, which can then recognize and destroy prostate cancer tumor cells.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
DCVAC/PCa: Prostate cancer

List of Figures
Figure 1: DCVAC/PCa for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 3: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: DCVAC/PCa drug profile
Table 2: DCVAC/PCa Phase III trial in prostate cancer
Table 3: DCVAC/PCa Phase I/II data in prostate cancer
Table 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll